JMP Securities Boosts Kura Oncology (NASDAQ:KURA) Price Target to $32.00

Kura Oncology (NASDAQ:KURAFree Report) had its price target boosted by JMP Securities from $22.00 to $32.00 in a report published on Wednesday morning, Benzinga reports. They currently have a market outperform rating on the stock.

Several other analysts have also issued reports on KURA. Mizuho started coverage on shares of Kura Oncology in a research report on Friday, December 22nd. They issued a buy rating and a $26.00 price target on the stock. HC Wainwright reaffirmed a buy rating and set a $32.00 price objective on shares of Kura Oncology in a research note on Friday, December 8th. StockNews.com started coverage on shares of Kura Oncology in a research note on Thursday, October 5th. They set a sell rating for the company. Finally, Wedbush reduced their price objective on shares of Kura Oncology from $40.00 to $37.00 and set an outperform rating for the company in a research note on Friday, November 3rd. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and an average price target of $28.28.

Check Out Our Latest Research Report on Kura Oncology

Kura Oncology Stock Performance

NASDAQ KURA opened at $21.13 on Wednesday. The company’s 50 day moving average is $14.12 and its 200-day moving average is $11.13. Kura Oncology has a 12-month low of $7.41 and a 12-month high of $22.92. The company has a quick ratio of 16.71, a current ratio of 16.71 and a debt-to-equity ratio of 0.02. The firm has a market cap of $1.57 billion, a P/E ratio of -10.46 and a beta of 0.85.

Kura Oncology (NASDAQ:KURAGet Free Report) last posted its quarterly earnings results on Thursday, November 2nd. The company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.06. Sell-side analysts predict that Kura Oncology will post -2.09 earnings per share for the current year.

Insiders Place Their Bets

In other Kura Oncology news, SVP Thomas James Doyle sold 2,318 shares of the business’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $17.80, for a total value of $41,260.40. Following the completion of the transaction, the senior vice president now owns 48,093 shares of the company’s stock, valued at approximately $856,055.40. The transaction was disclosed in a filing with the SEC, which is available through this link. In other news, CEO Troy Edward Wilson sold 91,052 shares of the business’s stock in a transaction that occurred on Wednesday, January 24th. The shares were sold at an average price of $20.23, for a total value of $1,841,981.96. Following the completion of the sale, the chief executive officer now directly owns 559 shares in the company, valued at approximately $11,308.57. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Thomas James Doyle sold 2,318 shares of the business’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $17.80, for a total transaction of $41,260.40. Following the completion of the sale, the senior vice president now owns 48,093 shares of the company’s stock, valued at $856,055.40. The disclosure for this sale can be found here. Insiders sold a total of 96,919 shares of company stock valued at $1,946,415 in the last quarter. Corporate insiders own 5.40% of the company’s stock.

Institutional Investors Weigh In On Kura Oncology

A number of hedge funds have recently made changes to their positions in KURA. Prosight Management LP bought a new stake in shares of Kura Oncology in the 2nd quarter worth approximately $14,213,000. State Street Corp lifted its holdings in shares of Kura Oncology by 44.1% in the 3rd quarter. State Street Corp now owns 4,368,763 shares of the company’s stock worth $59,677,000 after acquiring an additional 1,337,149 shares during the last quarter. Deerfield Management Company L.P. Series C lifted its holdings in shares of Kura Oncology by 35.1% in the 3rd quarter. Deerfield Management Company L.P. Series C now owns 4,374,044 shares of the company’s stock worth $39,891,000 after acquiring an additional 1,136,044 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of Kura Oncology by 14.7% in the 2nd quarter. BlackRock Inc. now owns 6,157,402 shares of the company’s stock worth $65,145,000 after acquiring an additional 788,095 shares during the last quarter. Finally, Affinity Asset Advisors LLC raised its holdings in Kura Oncology by 154.8% during the 2nd quarter. Affinity Asset Advisors LLC now owns 910,317 shares of the company’s stock valued at $9,631,000 after buying an additional 553,030 shares during the last quarter.

Kura Oncology Company Profile

(Get Free Report)

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase for the treatment of solid tumors and hematologic indications.

See Also

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.